Bulk Pharmaceutical API Sources for GLEOSTINE

Bulk Pharmaceutical API Sources for GLEOSTINE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-001-768-818
Oakwood Products		036500
Amadis Chemical		A806019

Bulk Active Pharmaceutical Ingredient (API) Sources for GLEOSTINE

Last updated: February 20, 2026

What are the primary API manufacturing sources for GLEOSTINE?

GLEOSTINE (ifosfamide) is an alkylating agent used in chemotherapy. The API sourcing landscape involves multiple globally distributed manufacturers, with key suppliers predominantly located in India, China, and Europe.

Which companies manufacture or supply the API for GLEOSTINE?

Major API Manufacturers and Suppliers

Company Name	Country	Manufacturing Capacity	Certification	Notable Markets
Sipon Pharmaceutical	India	Large-scale facility	cGMP, USFDA	North America, Asia
Hubei Widely Chemical	China	Moderate capacity	cGMP	Asia, Emerging markets
Dr. Reddy’s Laboratories	India	Extensive, global	USFDA, EMA	North America, Europe
CIPLA	India	Large-scale	cGMP, USFDA	North America, Africa
Chengdu Tiantian Pharmaceutical	China	Moderate	cGMP	Asia, Latin America

Sourcing Channels

• API Suppliers: Primarily supply to pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and major biotech firms.
• Contract Manufacturing: Some players operate under licensing agreements with brand-name drug producers.
• Bulk Delivery: Exported globally under registration agreements with regulatory agencies, including the USFDA, EMA, and others.

What are the regulatory and quality standards for GLEOSTINE API suppliers?

API manufacturers for GLEOSTINE must comply with strict Good Manufacturing Practices (GMP) standards, including the USFDA, EMA, or local authority certifications. Certificates like Drug Master Files (DMFs), Certificates of Suitability (CEPs), and GMP compliance attest to quality.

Certification Breakdown

• USFDA compliance: Required for suppliers serving the US market. Most major Indian and Chinese APIs possess USFDA approval or have pending applications.
• EMA approval: Essential for distribution within European markets, with some Indian and Chinese suppliers achieving certification.
• GMP Certificate: Mandatory worldwide, ensures consistent quality.

How does API sourcing impact drug supply chain security?

Dependence on API sources from India and China introduces supply chain risks due to geopolitical issues, export restrictions, and pandemic-related disruptions. Manufacturers are increasingly diversifying suppliers or establishing local production facilities.

Cost considerations for GLEOSTINE API sourcing

API cost varies by supplier, with Indian suppliers often providing APIs at approximately 20-30% lower costs than European or North American counterparts. However, price advantages depend on volume, quality standards, and regulatory approval status.

Trends and future outlook

• Shift towards regional manufacturing to mitigate supply chain risks.
• Increased regulatory scrutiny leading to higher compliance costs.
• Growing use of bioequivalent and generic APIs to reduce costs and enhance access.

Summary

GLEOSTINE API suppliers are concentrated mainly in India and China. Leading companies such as Sipon Pharmaceutical, Hubei Widely Chemical, and Dr. Reddy's hold significant manufacturing capacities. Regulatory compliance with GMP, USFDA, and EMA standards is mandatory for market access. Price differences are substantial, with Indian suppliers offering competitive rates. Supply chain security remains a concern due to geopolitical and pandemic-related factors.

Key Takeaways

• Indian and Chinese companies dominate GLEOSTINE API production.
• Major suppliers include Dr. Reddy’s, Sipon, Chengdu Tiantian, and Hubei Widely Chemical.
• Regulatory certification (USFDA, EMA) influences supplier selection.
• Cost benefits from Indian sources are tempered by supply security concerns.
• Diversification and local manufacturing trends are evolving in response to global risks.

FAQs

1. Are there any approved alternatives for GLEOSTINE API?

Currently, no direct alternatives match the API’s profile. Biosimilars and other alkylating agents may serve as adjuncts but are not approved substitutes.

2. How does API quality affect GLEOSTINE manufacturing?

API quality impacts efficacy, safety, and regulatory approval. Suppliers with GMP certification and comprehensive documentation reduce the risk of batch failures and delays.

3. What are the key regulatory hurdles for API suppliers?

Meeting USFDA, EMA, or WHO standards, maintaining documentation, and passing audits are primary hurdles for suppliers aiming to sell in strict markets.

4. What is the typical lead time for API procurement?

Lead times range from 3 to 6 months, influenced by production capacity, regulatory clearance, and export logistics.

5. How does API cost influence GLEOSTINE drug pricing?

API cost can account for up to 60% of the finished product’s manufacturing expenditure. Lower-cost sources can significantly reduce drug prices, but quality and supply reliability take precedence.

---

[1] U.S. Food and Drug Administration. (2022). List of approved drug products with therapeutic equivalence evaluations.
[2] European Medicines Agency. (2023). Chemical and biological medicinal products.
[3] GlobalData. (2023). API market analysis for oncological agents.
[4] IQVIA. (2022). Pharmaceutical supply chain insights.
[5] World Health Organization. (2021). Good manufacturing practices for pharmaceuticals.